<DOC>
	<DOCNO>NCT00190424</DOCNO>
	<brief_summary>The purpose study determine whether immunostimulating agent CpG-ODN effective treatment glioblastoma</brief_summary>
	<brief_title>Randomized Phase 2 With CpG-ODN Malignant Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>CPG-oligonucleotide</mesh_term>
	<criteria>Glioblastoma Karnofsky Performance Status â‰¥ 60 % Severe uncontrolled systemic disease Active autoimmune disease Uncontrolled epilepsia Platelets &lt; 100 000/mm3 ; Neutrophils &lt; 500 /mm3 ; lymphocytes &lt; 300/ mm3</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>